The role of P-glycoprotein in drug disposition: Significance to drug development

Drug-Drug Interactions

Volumn , Issue , 2001, Pages 295-357

  Troutman, Matthew D ^a   Luo, Gang ^b   Gan, Liang Shang ^b   Thakker, Dhiren R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 8844244311     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (319)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84(21): 7735-7738.
2. Hunter J, Hirst BH, Simmons NL. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 1993, 10(5): 743-749.
3. Hunter J, Hirst BH, Simmons NL. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. Br J Cancer 1991, 64(3): 437-444.
4. Ince P, Elliott K, Appleton DR, Moorghen M, Finney KJ, Sunter JP, Harris AL, Watson AJ. Modulation by verapamil of vincristine pharmacokinetics and sensitivity to metaphase arrest of the normal rat colon in organ culture. Biochem Pharmacol 1991, 41(8): 1217-1225.
5. Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 1996, 59(5): 541-549.
6. Meyers MB, Scotto KW, Sirotnak FM. P-glycoprotein content and mediation of vincristine efflux: correlation with the level of differentiation in luminal epithelium of mouse small intestine. Cancer Commun 1991, 3(5): 159-165.
7. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 1996, 13(4): 514-522.
8. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455(1): 152-162.
9. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983, 221(4617): 1285-1288.
10. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992,267(34): 24248-24252.
11. Kusuhara H, Suzuki H, Sugiyama Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 1998, 87(9): 1025-1040.
12. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989, 3(14): 2583-2592.
13. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989, 9(3): 1224-1232.
14. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdrl (Pglycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47(3): 381-389.
15. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996, 27(8): 1283-1291.
16. van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1988, 71(2): 401-411.
17. Smith AJ, Timmermans-Hereijgers JL, Roelofsen B, Wirtz KW, van Blitterswijk WJ, Smit II, Schinkel AH, Borst P. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994, 354(3): 263-266.
18. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986, 47(3): 371-380.
19. Gros P, Raymond M, Bell J, Housman D. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988, 8(7): 2770-2778.
20. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990, 10(4): 1652-1663.
21. Deuchars KL, Duthie M, Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992, 1130(2): 157-165.
22. Devine SE, Hussain A, Davide JP, Melera PW. Full length and alternatively spliced pgpl trancripts in multidrug-resistant Chinese hamster lung cells. J Biol Chem 1991, 266(7): 4545-4555.
23. Childs S, Ling V. Duplication and evolution of the P-glycoprotein genes in pig. Biochim Biophys Acta 1996, 1307(2): 205-212.
24. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human “MDRl” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987, 84(9): 3004-3008.
25. Schurr E, Raymond M, Bell JC, Gros P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdrl cDNA. Cancer Res 1989, 49(10): 2729-2733.
26. Buschman E, Gros P. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein. Cancer Res 1994, 54(18): 4892-4898.
27. Oude Elferink RPJ, tytgat GNJ, Groen AK. The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J 1997, 11: 19-28.
28. Fojo AT, Ueda K, Siamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84(1): 265-269.
29. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38(9): 1277-1287.
30. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986, 83(20): 7785-7789.
31. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988, 48(7): 1926-1929.
32. Sugawara I, Nakahama M, Hamada H, Tsuruo T, Mori S. Apparent stronger expression in the human adrenal cortex than in the human adrenal medulla of Mr 170,000180,000 P-glycoprotein. Cancer Res 1988, 48(16): 4611-4614.
33. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86(2): 695-698.
34. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham Me. Immunohistochemicallocalization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989, 37(2): 159-164.
35. Lieberman DM, Reithmeier RA, Ling V, Charuk JH, Goldberg H, Skorecki KL. Identification of P-glycoprotein in renal brush border membranes. Biochem Biophys Res Commun 1989, 162(1): 244-252.
36. Gan LS, Thakker, DR. Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv. Drug Delivery Rev. 1997, 23(1-3): 77-98.
37. Hosoya KI, Kim KJ, Lee VH. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm Res 1996, 13(6): 885-890.
38. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm Res 1998, 15(7): 1001-1006.
39. Horio M, Chin KV, Currier SJ, Goldenberg S, Williams C, Pastan I, Gottesman MM, Handler J. Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia. J Biol Chem 1989, 264(25): 14880-14884.
40. Hunter J, Hirst BH, Simmons NL. Transepithelial secretion, cellular accumulation and cytotoxicity of vinblastine in defined MDCK cell strains. Biochim Biophys Acta 1993, 1179(1): 1-10.
41. Zhang Y, Benet LZ. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDRJMDCK and Caco-2 cell monolayers. Pharm Res 1998, 15(10): 1520-1524.
42. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996, 49(2): 311-318.
43. Borst P, Schinkel AH. What have we learnt thus far from mice with disrupted Pglycoprotein genes? Eur J Cancer 1996, 32A(6): 985-990.
44. Borst P, Schinkel AH, Smit JI, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993, 60(2): 289-299.
45. Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 1995, 9(2): 319-336.
46. Kamimoto Y, Gatmaitan Z, Hsu J, Arias JM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989, 264(20): 11693-11698.
47. Pourtier-Manzanedo A, Boesch D, Loor F. FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. Anticancer Drugs 1991, 2(3): 279-283.
48. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, Thakker DR. Evidence for a polarized efflux system in CACO-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 1993, 197(2): 360-365.
49. Valverde MA, Bond TO, Hardy SP, Taylor JC, Higgins CF, Altamirano J, AlvarezLeefmans FJ. The multidrug resistance P-glycoprotein modulates cell regulatory volume decrease. EMBO J 1996, 15(17): 4460-4468.
50. Miwa A, Veda K, Okada Y. Protein kinase C-independent correlation between Pglycoprotein expression and volume sensitivity of Cl- channel. J Membr Biol 1997, 157(1): 63-69.
51. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRPI), in human cancer cell lines. Cancer Res 1997, 57(16): 3537-3547.
52. Kool M, van der Linden M, de Haas M, Baas F, Borst P. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 1999, 59(1): 175-182.
53. Masuda M, I’izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni’inuma K, Suzuki H, Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 1997, 57(16): 3506-3510.
54. Jansen PL, Peters WH, Lamers WH. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985, 5(4): 573-579.
55. Fernandez-Checa JC, Takikawa H, Horie T, Ookhtens M, Kaplowitz N. Canalicular transport of reduced glutathione in normal and mutant Eisai hyperbilirubinemic rats. J Biol Chem 1992, 267(3): 1667-1673.
56. Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, de Haas M, Smith AJ, Broxterman HJ, Mulder NH, de Vries EG, Baas F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993, 53(8): 1747-1750.
57. Stride BD, Valdimarsson G, Gerlach JH, Wilson GM, Cole SP, Deeley RG. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 1996, 49(6): 962-971.
58. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996, 148(4): 1237-1247.
59. Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, Oude Elferink RP, Borst P, Schinkel AH. Basolaterallocalization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996, 97(5): 1211-1218.
60. Muller M, Jansen PL. Molecular aspects of hepatobiliary transport. Am J Physiol 1997,272(6 PI. 1): G1285-G1303.
61. Torok M, Gutmann H, Fricker G, Drewe J. Sister of P-glycoprotein expression in different tissues. Biochem Pharmacol 1999, 57(7): 833-835.
62. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier P. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998, 273(16): 10046-10050.
63. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDRI/P-glycoprotein. Mol Pharmacol 2000, 57(1): 24-35.
64. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 1997, 160(3): 161-175.
65. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992,8: 67-113.
66. Leveille-Webster CR, Arias JM. The biology of the P-glycoproteins. J Membr Biol 1995, 143(2): 89-102.
67. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Biochemistry 1993, 62: 385-427.
68. German UA. P-glycoprotein-a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996, 32A(6): 927-944.
69. Endicott JA, Ling V. The biochemistry ofP-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989, 58: 137-171.
70. Richert ND, Aldwin L., Nitecki D, Gottesman MM, Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant. Biochemistry 1988, 27(20): 7607-7613.
71. Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 1988, 85(11): 3762-3766.
72. Beck WT, Cirtain MC. Continued expression of vinca alkaloid resistance by CCRFCEM cells after treatment with tunicamycin or pronase. Cancer Res 1982, 42(1): 184-189.
73. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR. Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983, 67(10): 869-874.
74. Germann UA, Willingham MC, Pastan I, Gottesman MM. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 1990, 29(9): 2295-2303.
75. Kuchler K, Thorner J. Functional expression of human mdrl in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1992, 89(6): 2302-2306.
76. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drugstimulated membrane ATPase. J Biol Chem 1992, 267(7): 4854-4858.
77. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. N-glycosylation and deletion mutants of the human MDRI P-glycoprotein. J Biol Chem 1993, 268(10): 7474-7481.
78. Kramer R, Weber TK, Areci R, Ramchurren N, Kastrinakis WV, Steele GJ, Sum- merhayes Ie. Inhibition of N-Iinked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995, 71(4): 670-675.
79. Chambers TC, Germann VA, Gottesman MM, Pastan I, Kuo JF, Ambudkar SY. Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry 1995, 34(43): 14156-14162.
80. Orr GA, Han EK, Browne PC, Nieves E, O’Connor BM, Yang CP, Horwitz SB. Identification of the major phosphorylation domain of murine mdrlb P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites. J Biol Chem 1993, 268(33): 25054-25062.
81. Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, Bates SE. Bryostatin I affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin Cancer Res 1995, 1(12): 1581-1587.
82. Higgins CF. P-glycoprotein and cell volume-activated chloride channels. J Bioenerg Biomembr 1995, 27(1): 63-70.
83. Boyum R, Guidotti G. Effect of ATP binding cassette/rnultidrug resistance proteins on ATP efflux of accharomyces cerevisiae. Biochem Biophys Res Commun 1997, 230(1): 22-26.
84. Tominaga M, Tominaga T, Miwa A, Okada Y. Volume-sensitive chloride channel activity does not depend on endogenous P-glycoprotein. J Biol Chem 1995, 270(46): 27887-27893.
85. Homolya L, Hollo Z, Germann VA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993, 268(29): 21493-21496.
86. Currier SJ, Veda K, Willingham MC, Pastan I, Gottesman MM. Deletion and insertion mutants of the multidrug transporter. J Biol Chem 1989, 264(24): 14376-14381.
87. Loo TW, Clarke DM. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 1994, 269(10): 7750-7755.
88. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann VA, Pastan J. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995, 29: 607-649.
89. Bruggemann EP, Currier SJ, Gottesman MM, Pastan J. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992, 267(29): 21020-21026.
90. Loo TW, Clarke DM. Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TMI2 of human P-glycoprotein by drug substrates. J Biol Chem 1996, 271(44): 27482-27487.
91. Loo TW, Clarke DM. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993, 268(27): 19965-19972.
92. Loo TW, Clarke DM. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 1994, 33(47): 14049-14057.
93. Ueda K, Taguchi Y, Morishima M. How does P-glycoprotein recognize its substrates? Semin Cancer Biol 1997,8(3): 151-159.
94. Kajiji S, Talbot F, Grizzuti K, Van Dyke-Phillips V, Agresti M, Safa AR, Gros P. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site. Biochemistry 1993, 32(16): 4185-4194.
95. Gros P, Dhir R, Croop J, Talbot F. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdrl and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 1991, 88(16): 7289-7293.
96. Germann VA, Pastan I, Gottesman MM. P-glycoproteins: mediators of muItidrug resistance. Semin Cell Biol 1993, 4(1): 63-76.
97. Sharom FJ. The P-glycoprotein multidrug transporter: interactions with membrane lipids, and their modulation of activity. Biochem Soc Trans 1997, 25(3): 1088-1096.
98. Pawagi AB, Wang J, Silvertnan M, Reithmeier RA, Deber CM. Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity. J Mol Biol 1994, 235(2): 554-564.
99. Schinkel AH, Roelofs EM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991, 51(10): 2628-2635.
100. Tarnai I, Safa AR. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991, 266(25): 16796-16800.
101. Ferry DR, Russell MA, Cullen MH. P-glycoprotein possesses a 1,4-dihydropyridine- selective drug acceptor site which is alloserically coupled to a vinca-alkaloidselective binding site. Biochem Biophys Res Commun 1992, 188(1): 440-445.
102. Ferry DR, Malkhandi PJ, Russell MA, Kerr OJ. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochern Phartnacol 1995, 49(12): 1851-1861.
103. Shapiro AB, Ling V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 1997, 250(1): 130-137.
104. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation ofP-glycoprotein as a putative mechanism. Biochem Pharmacol 1994, 48(7): 1437-1445.
105. Phang JM, Poore CM, Lopaczynska J, Yeh GC. Flavonol-stimulated efflux of?,12dimethylbenz(a)anthracene in multidrug-resistant breast cancer cells. Cancer Res 1993, 53(24): 5977-5981.
106. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochern Sci 1992, 17(1): 18-21.
107. Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 1992, 267(35): 24995-25002.
108. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDRI P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996, 87(3): 507-517.
109. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1997, 1361(2): 159-168.
110. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochern 1998, 251(1-2): 252-261.
111. Scala S, Akhmed N, Rao US, Paull K, Lan LB, Dickstein B, Lee JS, Elgemeie GH, Stein WD, Bates SE. P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Phannacol 1997, 51(6): 1024-1033.
112. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1997, 1361(2): 169-176.
113. Etievant C, Schambel P, Guminski Y, Barret JM, Imbert T, Hill BT. Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series. Anticancer Drug Des 1998, 13(4): 317-336.
114. Bain LJ, LeBlanc GA. Interaction of structurally diverse pesticides with the human MDR1gene product P-glycoprotein. Toxicol Appl Phannacol 1996, 141(1): 288-298.
115. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Phannacol 1989, 35(1): 105-115.
116. Regev R, Assaraf YG, Eytan GD. Membrane fluidization by ether, other anesthetics, and certain agents abolishes P-glycoprotein ATPase activity and modulates efflux from multidrug-resistant cells. Eur J Biochem 1999, 259(1-2): 18-24.
117. Simons K, van Meer G. Lipid sorting in epithelial cells. Biochemistry 1988, 27(17): 6197-6202.
118. Eytan GD, Regev R, Oren G, Assaraf YG. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996, 271(22): 12897-12902.
119. Regev R, Eytan GD. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Phannacol 1997, 54(10): 1151-1158.
120. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996, 13(4): 528-534.
121. Nerurkar MM, Ho NF, Burton PS, Vidmar TI, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 1997, 86(7): 813-821.
122. Pinto M., Robine-Leon S., Appay M.-D., Kedinger M., Triadou N., Dussaulx E.B., Croix B., Simon-Assmann P., Haffen K., Fogh J., Zweibaum A. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol. Cell 1983,47: 323-330.
123. Hidalgo II, Raub TI, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989, 96(3): 736-749.
124. Artursson P. Epithelial transport of drugs in cell culture. I: a model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 1990, 79(6): 476-482.
125. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 1991, 8(4): 305-330.
126. Wilson G, Hassan I, Dix C, Williamson I, Shah R, Mackay M, Artursson P. Transport and permeability properties of human Caco-2 cells: an in vitro model of the intestinal epithelial cell barrier. J Control. Release 1990, 11: 25-40.
127. Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990, 7(9): 902-910.
128. Cogburn IN, Donovan MG, Schasteen CS. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res 1991, 8(2): 210-216.
129. Chantret I, Barbat A, Dussaulx E, Brattain MG, Zweibaum A. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 1988, 48(7): 1936-1942.
130. Burton PS, Conradi RA, Hilgers AR, Ho NF. Evidence for a polarized efflux system for peptides in the apical membrane of Caco-2 cells. Biochem Biophys Res Commun 1993, 190(3): 760-766.
131. Briske-Anderson MJ, Finley JW, Newman SM. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 1997, 214(3): 248-257.
132. Lankelma J, Mulder HS, van Mourik F, Wong Fong Sang HW, Kraayenhof R, van Grondelle R. Cellular daunomycin fluorescence in multidrug resistant 2780AD cells and its relation to cellular drug localisation. Biochim Biophys Acta 1991, 1093(23): 147-152.
133. Molinari A, Cianfriglia M, Meschini S, Calcabrini A, Arancia G. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer 1994, 59(6): 789-795.
134. Schuurhuis GJ, van Heijningen TH, Cervantes A, Pinedo HM, de Lange JH, Keizer HG, Broxterman HJ, Baak JP, Lankelma J. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. Br J Cancer 1993, 68(5): 898-908.
135. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, Watkins PB. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of I alpha,25-dihydroxyvitamin 03. Mol Pharmacol 1997, 51(5): 741-754.
136. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, WunderliAllenspach H, Merkle HP, Langguth P. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 1998, 87(6): 757-762.
137. Simons K, Fuller SD. Cell surface polarity in epithelia. Annu Rev Cell Biol 1985, 1: 243-288.
138. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RP, Baas F, Schinkel AH, Borst P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) eDNA. J Clin Invest 1998, 101(7): 1310-1319.
139. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998, 70(5): 1781-1792.
140. Bradbury MW. The blood-brain barrier. Exp Physiol 1993, 78(4): 453-472.
141. Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Delivery Rev 1999, 36: 179-194.
142. Tsuji A, Tarnai II. Blood-brain barrier function ofP-glycoprotein. Adv Drug Delivery Rev 1997, 25(2,3): 287-298.
143. Audus KL, Ng L, Wang W, Borchardt RT. Models for assessing drug absorption and metabolis. In: RT Borchardt, G Wilson, eds. Brain Microvessel Endothelial Cell Culture Systems, 1996, New York: Plenum Press, pp 239-258.
144. Audus KL, Borchardt RT. Characteristics of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers. J Neurochem 1986, 47(2): 484-488.
145. Audus KL, Borchardt RT. Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier. Ann N Y Acad Sci 1987, 507: 9-18.
146. Betz AL, Firth JA, Goldstein GW. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res 1980, 192(1): 17-28.
147. Borges N, Shi F, Azevedo I, Audus KL. Changes in brain microvessel endothelial cell monolayer permeability induced by adrenergic drugs. Eur J Pharmacol 1994, 269(2): 243-248.
148. Drewes LD, Lidinsky WA. Studies of cerebral capillary endothelial membrane. Adv Exp Med Biol 1980, 131: 17-27.
149. Guillot FL, Audus KL. Angiotensin peptide regulation of fluid-phase endocytosis in brain microvessel endothelial cell monolayers. J Cereb Blood Flow Metab 1990, 10(6): 827-834.
150. Miller DW, Audus KL, Borchardt RT. Application of cultured endothelial cells of the brain microvasculature in the study of the blood-brain barrier. J Tissue Cult Methods 1992, 14: 217-224.
151. Raub TJ, Audus KL. Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers. J Cell Sci 1990, 97(Pt 1): 127-138.
152. Joo F. The blood-brain barrier in vitro: ten years of research on microvessels isolated from the brain. Neurochem Int 1985, 7: 1-25.
153. Joo F. The cerebral microvessels in culture, an update. J Neurochem 1992, 58(1): 1-17.
154. Joo F. The blood-brain barrier in vitro: the second decade. Neurochem Int 1993, 23(6): 499-521.
155. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tarnai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 1992, 51(18): 1427-1437.
156. Crone C. The blood-brain barrier as a tight epithelium: where is information lacking? Ann NY Acad Sci 1986,481: 174-185.
157. Fontaine M, Elmquist WF, Miller DW. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci 1996, 59(18): 1521-1531.
158. Lechardeur D, Scherman D. Functional expression of the P-glycoprotein mdr in primary cultures of bovine cerebral capillary endothelial cells. Cell Biol Toxicol 1995, 11(5): 283-293.
159. Regina A, Koman A, Piciotti M, EI Hafny B, Center MS, Bergmann R, Couraud PO, Roux F. Mrpl multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998, 71(2): 705-715.
160. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 1998, 70(3): 1151-1159.
161. 16l. Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, Miller DW. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun 1998, 243(3): 816-820.
162. Shirai A, Naito M, Tatsuta T, Dong J, Hanaoka K, Mikami K, Oh-hara T, Tsuruo T. Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1994, 1222(3): 400-4004.
163. Tsuji A, Tarnai I, Sakata A, Tenda Y, Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993, 46(6): 1096-1099.
164. Glynn SL, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998, 87(3): 306-310.
165. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. Role of P-glycoprotein on the CNS disposition of amprenavir (14IW94), an HIV protease inhibitor. Pharm Res 1999, 16(8): 1206-1212.
166. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL. Pglycoprotein- mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 1999, 58(6): 951-957.
167. Egleton RD, Abbruscato TJ, Thomas SA, Davis TP. Transport of opioid peptides into the central nervous system. J Pharm Sci 1998, 87(11): 1433-1439.
168. Henthorn TK, Liu Y, Mahapatro M, Ng KY. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 1999, 289(2): 1084-1089.
169. Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos 1999, 20(2): 85-90.
170. Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regul 1994, 34: 371-380.
171. 17l. Kwon Y, Kamath AV, Morris ME. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles. J Pharm Sci 1996, 85(9): 935-939.
172. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988, 85(10): 3580-3584.
173. Hsing S, Gatmaitan Z, Arias JM. The function of Gp170, the multidrug-resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992, 102(3): 879-885.
174. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco2 cells. Pharm Res 1998, 15(8): 1160-1167.
175. Dutt A, Heath LA, Nelson JA. P-glycoprotein and organic cation secretion by the mammalian kidney. J Pharmacol Exp Ther 1994, 269(3): 1254-1260.
176. Saitoh H, Aungst BJ. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 1995, 12(9): 1304-1310.
177. Emi Y, Tsunashima D, Ogawara K, Higaki K, Kimura T. Role of P-glycoprotein as a secretory mechanism in quinidine absorption from rat small intestine. J Pharm Sci 1998, 87(3): 295-299.
178. Hashimoto Y, Sasa H, Shimomura M, Inui K. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998, 15(10): 1609-1613.
179. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996, 24(2): 142-147.
180. Beja O, Bibi E. Functional expression of mouse Mdrl in an outer membrane permeability mutant of Escherichia coli. Proc Natl Acad Sci USA 1996, 93(12): 5969-5974.
181. Evans GL, Ni B, Hrycyna CA, Chen D, Ambudkar SV, Pastan I, Germann UA, Gottesman MM. Heterologous expression systems for P-glycoprotein: E. coli, yeast, and baculovirus. J Bioenerg Biomembr 1995, 27(1): 43-52.
182. Castillo G, Vera JC, Yang CP, Horwitz SB, Rosen OM. Functional expression of murine multidrug resistance in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1990, 87(12): 4737-4741.
183. Saeki T, Shimabuku AM, Azuma Y, Shibano Y, Komano T, Ueda K. Expression of human P-glycoprotein in yeast cells-effects of membrane component sterols on the activity of P-glycoprotein. Agric Biol Chem 1991, 55(7): 1859-1865.
184. Raymond M, Gros P, Whiteway M, Thomas DY. Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. Science 1992, 256(5054): 232-234.
185. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 1998, 36(1): 16-24.
186. Bucana CD, Giavazzi R, Nayar R, O’Brian CA, Seid C, Earnest LE, Fan D. Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. Exp Cell Res 1990, 190(1): 69-75.
187. Dhar S, Nygren P, Liminga G, Sundstrom C, de la Torre M, Nilsson K, Larsson R. Relationship between cytotoxic drug response patterns and activity of drug efflux transporters mediating multidrug resistance. Eur J Pharmacol 1998, 346(2-3): 315-322.
188. Efferth T, Lohrke H, Volm M. Reciprocal correlation between expression of p_ glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 1989, 9(6): 1633-1637.
189. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994, 46(4): 627-638.
190. Liminga G, Nygren P, Larsson R. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. Exp Cell Res 1994, 212(2): 291-296.
191. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam, and ketoconazole in CaCo-2 cells. Eur J Pharmacol 1998, 358(3): 284-294.
192. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs 1996, 7(5): 568-578.
193. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 1999, 289(1): 149-155.
194. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, SpahnLangguth H. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther 1999, 288(1): 348-357.
195. Bohme M, Buchler M, Muller M, Keppler D. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte cannilicular membrane. FEBS Lett 1993, (1-2): 193-196.
196. Drueckes P, Schinzel R, Palm D. Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal Biochem 1995, 230(1): 173-177.
197. Lennemas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol 1997, 49(7): 627-638.
198. Saitoh H, Hatakeyama M, Eguchi O, Oda M, Takada M. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J Pharm Sci 1998, 87(1): 73-75.
199. Brouwer KLR, Thruman RG. Isolated perfused liver. In: Borchardt RT, Smith PL, Wilson G, eds. Models for Assessing Drug Absorption and Metabolism. 1996, New York: Plenum Press, pp 161-192.
200. Booth CL, Brouwer KR, Brouwer KL. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Cancer Res 1998, 58(16): 3641-3648.
201. Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M, Sugiyama Y. Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol 1992, 16(12): 77-88.
202. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993, 266(3): 1620-1625.
203. Smith QR, Takasato Y. Kinetics of amino acid transport at the blood-brain barrier studied using an in situ brain perfusion technique. Ann NY Acad Sci 1986, 481: 186-201.
204. Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. In: Borchardt RT, Wilson G, Smith PL, eds. Models for Assessing Drug Absorption and Metabolism. 1996, New York: Plenum Press, pp 285-307.
205. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 1984, 247(3 Pt 2): H484-H493.
206. Smit JW, Duin E, Steen H, Oosting R, Roggeveld J, Meijer DK. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br 1 Pharmacol 1998, 123(3): 361-370.
207. Booth CL, Pollack GM, Brouwer KL. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the ratelimiting steps and potential sites of drug interactions. Hepatology 1996, 23(4): 771-780.
208. Hayes JH, Soroka C, Rios-Velez L, Boyer JL. Hepatic sequestration and modulation of the canalicular transport of the organic cation, daunorubicin, in the Rat. Hepatology 1999, 29(2): 483-493.
209. Smith QR, Nagura H, Takada Y, Duncan MW. Facilitated transport of the neurotoxin, beta-N-methylamino-L-alanine, across the blood-brain barrier. J Neurochem 1992, 58(4): 1330-1337.
210. Murata M, Tarnai I, Kato H, Nagata O, Tsuji A. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier. J Pharmacol Exp Ther 1999, 290(1): 51-57.
211. Drion N, Lemaire M, Lefauconnier JM, Scherrmann JM. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. 1 Neurochem 1996, 67(4): 1688-1693.
212. Drion N, Risede P, Cholet N, Chanez C, Scherrmann JM. Role of P-170 glycoprotein in colchicine brain uptake. J Neurosci Res 1997, 49(1): 80-88.
213. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000, 57(4): 679-686.
214. Chikhale EG, Burton PS, Borchardt RT. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J Pharmacol Exp Ther 1995, 273(1): 298-303.
215. Lemaire M, Bruelisauer A, Guntz P, Sato H. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats. Cancer Chemother Pharmacol 1996, 38(5): 481-486.
216. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdrla P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 2000, 20: 381-386.
217. Groen AK, Van Wijland MJ, Frederiks WM, Smit JJ, Schinkel AH, Oude Elferink RP. Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 1995, 109(6): 1997-2006.
218. Oude Elferink RP, Ottenhoff R, van Wijland M, Smit JJ, Schinkel AH, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995, 95(1): 31-38.
219. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JR, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP1, Berns, AJM, Borst P. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77(4): 491-502.
220. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A(7-8): 1295-1298.
221. Schinkel AH. Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Ther 1998, 36(1): 9-13.
222. Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75(3): 451-462.
223. Smit JW, Schinkel AH, Weert B, Meijer DK. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdrla and mdrlb genes have been disrupted. Br J Pharmacol 1998, 124(2): 416-424.
224. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9(3): 1346-1350.
225. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988, 85(12): 4350-4354.
226. van de Vrie W, Marquet RL, Stoter G, De Bruijn EA, Eggermont AM. In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 1998, 35(1): 1-57.
227. Endicott JA, Sarangi F, Ling V. Complete eDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 1991, 2(2): 89-101.
228. Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 1991, 106(2): 229-236.
229. Hsu SI, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 1989, 264(20): 12053-12062.
230. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdrla P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995, 96(4): 1698-1705.
231. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 1996, 88(14): 994-999.
232. Galski H, Sullivan M, Willingham MC, Chin KV, Gottesman MM, Pastan I, Merlino GT. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol 1989, 9(10): 4357-4363.
233. Mickisch GH, Pastan I, Gottesman MM. Multidrug resistant transgenic mice as a novel pharmacologic tool. Bioessays 1991, 13(8): 381-387.
234. Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991, 88(2): 547-551.
235. Mickisch GH, Rahman A, Pastan I, Gottesman MM. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 1992, 84(10): 804-805.
236. Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997, 77(2): 545-590.
237. Walle UK, Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 1998, 26(4): 343-346.
238. Terao T, Hisanaga E, Sai Y, Tarnai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996, 48(10): 1083-1089.
239. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer OK, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997, 94(5): 2031-2035.
240. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker DR. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996, 24(3): 344-349.
241. Ferry DR. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 1998, 36(1): 29-40.
242. Arimori K, Nakano M. Drug exsorption from blood into the gastrointestinal tract. Pharm Res 1998, 15(3): 371-376.
243. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997,40(40 Suppl): S3-S8.
244. Aszalos A, Ross DO. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs. Anticancer Res 1998, 18(4C): 2937-2944.
245. Wang Q, Yang H, Miller OW, Elmquist WF. Effect of the P-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats. Biochem Biophys Res Commun 1995, 211(3): 719-726.
246. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Delivery Rev 1997, 27(2,3): 201-214.
247. Smit JW, Schinkel AH, Muller M, Weert B, Meijer OK. Contribution of the murine mdrla P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdrla gene disruption. Hepatology 1998,27(4): 1056-1063.
248. Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996, 18(4): 350-356.
249. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999, 27(8): 866-871.
250. Chen C, Pollack GM. Altered disposition and antinociception of [D-penicilla- mine(2,5)] enkephalin in mdrla-gene-deficient mice. J Pharmacol Exp Ther 1998, 287(2): 545-552.
251. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994, 4(5): 247-259.
252. Seree E, Villard PH, Hever A, Guigal N, Puyoou F, Charvet B, Point-Scomma H, Lechevalier E, Lacarelle B, Barra Y. Modulation of MDRI and CYP3A expression by dexamethasone: evidence for an inverse regulation in adrenals. Biochem Biophys Res Commun 1998, 252(2): 392-395.
253. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995, 13(3): 129-134.
254. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997, 283(3): 1552-1562.
255. Fisher JM, Wrighton SA, Watkins PB, Schmiedlin-Ren P, Calamia JC, Shen DD, Kunze KL, Thummel KE. First-pass midazolam metabolism catalyzed by lalpha,25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 1999, 289(2): 1134-1342.
256. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999, 16(3): 408-414.
257. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Delivery Rev 1997, 27(2,3): 161-170.
258. Benet LZ, Izumi T, Zhang Y, Silverman JA, Wacher VI. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 1999, 62(1-2): 25-31.
259. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998, 87(11): 1322-1330.
260. Mayer D, Wagenaar E, Beijnen JH, Smit JW, Meijer OK, van Asperen J, Borst P, Schinkel AH. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. BrJ Pharmacol 1996, 119(5): 1038-1044.
261. van Asperen J, van Tellingen O, Beijnen JH. The role of mdrla P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 2000, 28(3): 264-267.
262. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998, 10(Suppl 1): S15-S19.
263. Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995, 15(2): 331-336.
264. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41(5): 1967-1972.
265. Cantwell B, Buamah P, Harris AL. Phase I and II study of oral verapamil and intravenous vindesine. Proc Am Soc Clin Oncol 1985,42: 161.
266. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 1991, 83(2): 105-110.
267. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986, 18(3): 239-242.
268. Gigante M, Toffoli G, Boiocchi M. Pharmacokinetics of doxorubicin co-administered with high-dose verapamil. Br J Cancer 1995, 71(1): 134-136.
269. Millward MJ, Cantwell BM, Munro NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993, 67(5): 1031-1035.
270. Milroy R. A randomized clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 1993, 68(4): 813-818.
271. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest Oncology Group study. Cancer 1995, 75(3): 815-820.
272. Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CYAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Res Treat 1997, 42(1): 7-14.
273. Kronbach T, Fischer Y, Meyer VA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988, 43(6): 630-635.
274. Colombo T, Zucchetti M, D’Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 1994, 269(1): 2227.
275. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992, 10(10): 1635-1642.
276. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic S. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994, 12(4): 835-842.
277. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 1984, 44(10): 4303-4307.
278. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Em J Cancer 1992, 28(1): 28-31.
279. Yerrelle P, Meissonnier F, Fonck Y, Feillel Y, Dionet C, Kwiatkowski F, Plagne R, Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 1991, 83(2): 111-116.
280. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992, 10(11): 1730-1736.
281. Wigler PW. Cellular drug efflux and reversal therapy of cancer. J Bioenerg Biomembr 1996, 28(3): 279-284.
282. Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992, 66(5): 833-839.
283. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistancereversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992, 84(23): 1811-1816.
284. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996, 32A(6): 1070-1081.
285. Samuels BL, Hollis DR, Rosner GL, Trump DL, Shapiro CL, Vogelzang NJ, Schilsky RL. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res 1997, 3(11): 1977-1984.
286. Smith DC, Trump DL. A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 1995, 36(1): 65-68.
287. Wilisch A, Haussermann K, Noller A, Probst H, Gekeler V. MDR modulating and antineoplastic efects of B859-035, the (-)isomer of niguldipine. J Cancer Res Clin Oncol 1991, 117: S110.
288. Ferry DR, Glossmann H, Kaumann AJ. Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br J Pharmacol 1985, 84(4): 811-824.
289. Wilson WH, Bates SE, Fojo A, Chabner BA. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas. J Cancer Res Clin Oncol 1995, 121 Suppl 3: R25-R29.
290. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995, 13(8): 1985-1994.
291. Tolchner AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MH, Denicoff AM, Barnes CS, Gossard MR, Retsch PA, Berg SL, Balis FM, Venzan DJ, O’Shaughnessy JA. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996, 14(4): 1173-1184.
292. Dhainaut A, Regnier G, Atassi G, Pierre A, Leonce S, Kraus-Berthier L, Prost JF. New triazine derivatives as potent modulators of multidrug resistance. J Med Chem 1992, 35(13): 2481-2496.
293. Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH, Hecquet B, Lucas C, Gerard B, Bleiberg H. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br 1 Cancer 1997, 76(10): 1376-1381.
294. Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla IP, Negrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemother Pharmacol 1998, 41(4): 281-291.
295. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53(19): 4595-4602.
296. Sparreboom A, Planting AS, Iewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WI, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDRI P-glycoprotein. Anticancer Drugs 1999, 10(8): 719-728.
297. te Boekhorst PA, van KapeIJ, Schoester M, Sonneveld P. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdrl phenotype. Cancer Chemother Pharmacol 1992, 30(3): 238-242.
298. Glisson B, Gupta R, Hodges P, Ross W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res 1986, 46(4 Pt 2): 1939-1942.
299. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiemik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 1999, 457: 47-56.
300. Komblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli D, Snell V, SanchezWilliams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. 1 Clin Oncol 1997, 15(5): 1796-1802.
301. Lee EI, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. J Clin Oncol 1999, 17(9): 2831-2839.
302. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WI, Eeltink C, Vermorken JB, Pinedo HM. A dose-finding and pharmacokinetic study ofreversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997, 3(11): 2005-2015.
303. Yamazaki M, Suzuki H, Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 1996, 13(4): 497-513.
304. Adams DI, Knick VC. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine). Invest New Drugs 1995, 13(1): 13-21.
305. Yu OK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999, 39(12): 1203-1211.
306. Mackstaller LL, Alpert JS. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol 1997, 20(7): 640-650.
307. Cobbe SM. Using the right drug. A treatment algorithm for atrial fibrillation. Eur Heart J 1997, 18 Suppl C: C33-C39.
308. de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992, 189(1): 551-557.
309. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998, 64(1): 123-128.
310. Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanisms: Ann Pharmacother 1997, 31(4): 438-440.
311. Ito S, Woodland C, Harper PA, Koren G. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci 1993, 53(2): PL25-PL31.
312. Brody TM, Lamer J, Minneman RG. Human Pharmacology: Molecular to Clinical. 3rd ed. 1998, St. Louis: Mosby-Year Book.
313. Kelly RA, Smith TW. Pharmacological treatment of heart failure. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. The pharmacological basis of therapeutics. 9th ed. 1996, New York: McGraw-Hill, pp 809-838.
314. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol 1998, 40(1): 45-46.
315. Pedersen KE. Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Acta Med Scand Suppl 1985, 697: 1-40.
316. Johne A, Brockrnoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999, 66(4): 338-345.
317. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999, 104(2): 147-153.
318. Theis JG, Chan HS, Greenberg ML, Malkin D, Karaskov V, Moncica I, Koren G, Doyle J. Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin. Int J Clin Pharmacol Ther 1998, 36(2): 61-64.
319. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996, 59(3): 297-303.